Navigation Links
InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe
Date:12/17/2010

e conference ID# 33188579.  The webcast will remain available on the company's website until the next earnings call.

About Esbriet (pirfenidone)

Preclinical and in-vitro evidence has shown that Esbriet has both anti-fibrotic and anti-inflammatory effects.  In February 2009, InterMune announced the results of the company's two pivotal Phase 3 clinical trials evaluating Esbriet for the treatment of IPF, known as the CAPACITY trials.  In clinical studies, Esbriet was safe and generally well-tolerated, with the most frequent side effects reported being photosensitivity rash and gastrointestinal symptoms.  Since 2008, pirfenidone has been marketed in Japan as Pirespa® by Shionogi & Co. Ltd.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.  InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections.  The pulmonology portfolio includes Esbriet™ (pirfenidone) for which InterMune has completed a Phase 3 program in patients with IPF (CAPACITY).  The Marketing Authorization Application (MAA) for Esbriet received a positive CHMP opinion that is now awaiting ratification by the European Commission.  The hepatology portfolio includes next-generation HCV protease inhibitor and NS5A research programs.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to the anticipated receipt
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. InterMune to Release Third Quarter Financial Results on October 28
2. InterMune Sells Danoprevir Rights to Roche for $175 Million
3. InterMune to Present at 2010 Citi Health Care Conference
4. InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
5. InterMune to Release First Quarter Financial Results on April 29
6. InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
7. InterMune Announces Proposed Public Offering of Common Stock
8. InterMune to Release Third Quarter Financial Results on November 5
9. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
10. InterMune to Present at Canaccord Adams Conference
11. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... , Aug. 26, 2014 An analysis ... structures of all Dengue virus strains in Pubmed, has ... back to 1944. This conservation and sharing of specific ... Synthetic Dengue Blocker-Vaccine™ candidate, as it did for the ... both of which have been found to be effective ...
(Date:8/26/2014)... , Aug. 26, 2014   Lycera Corp ... breakthrough oral medicines to treat autoimmune disease and ... today announced the appointment of Harinder Singh ... advisory board.  Dr. Singh will lead the board,s ... Lycera,s multiple ongoing research programs and pipeline of ...
(Date:8/26/2014)... The global market for molecular diagnostics ... according to a new study by Grand View Research, ... the subsequent introduction of advanced cancer diagnostic technologies are ... the next six years. Moreover, the growing global base ... coupled with disease triggering lifestyle habits such as smoking ...
(Date:8/26/2014)... (PRWEB) August 26, 2014 Genedata, ... drug discovery and life science research, today announced ... will be held in Asia, Europe, and ... global pharmaceutical companies and leading research organizations will ... best practices, case studies, and upcoming challenges in ...
Breaking Biology Technology:Lycera Appoints Harinder Singh, Ph.D., as Chair of Scientific Advisory Board 2Lycera Appoints Harinder Singh, Ph.D., as Chair of Scientific Advisory Board 3World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 2World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 3World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 4World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 5World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 6Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 2Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 3
... Sept. 20 HelixLife™ recently launched the following ... (Vitamins & Skin Serum), Anti-Acne Skin Serum, Foundational ... lines were developed in partnership with GeneLink BioSciences, ... personal health and skin care using GeneLink,s advanced ...
... Sept. 20 Epitomics, Inc. today announced that The ... chosen the company to distribute a panel of LRRK2 ... the two parties. Under a special arrangement the antibodies ... PD research community to help advance LRRK2 therapeutic development ...
... a central alternative to petroleum-based energy production. However, current ... yield and is more expensive to mass-produce. In addition, ... on the environment is incomplete, experts say. To ... of solar power, a research team from Rochester Institute ...
Cached Biology Technology:HelixLife Launches Custom Health Supplements, Anti-Aging and Acne Skin Serums 2Epitomics, Inc. Announces Worldwide Availability of LRRK2 Antibodies Developed in Partnership With The Michael J. Fox Foundation 2Research team assesses environmental impact of organic solar cells 2
(Date:8/26/2014)... , August 26, 2014 ... von Oxygen Forensic Passware Analyst bekannt, einem ... preisgekrönten Erfassungs- und Analysetools von Oxygen mit ...     Das neue Tool kombinierte ... einem einzigen nahtlosen Ablauf. Das neu hinzugekommene ...
(Date:8/25/2014)... of the first U.S. outbreaks of the H1N1 virus ... 2,000 people. A university math and biology professor has ... to gain insight into how only a few infected ... university community., The fall 2009 semester hadn,t even started ... Health and Wellness Services clinic11 one day, and just ...
(Date:8/25/2014)... University of California, San Diego School of Medicine have found ... the primary form of a deadly brain cancer are ... DNA sequence of the tumor, but in its epigenetic signature. ... in the journal Oncotarget . , "There is ... DNA of the cancer cell," said Clark Chen, MD, PhD, ...
Breaking Biology News(10 mins):Oxygen Forensic Passware Analyst erfasst geschützte Mobilgerätedaten 2WSU flu outbreak provides rare study material 2WSU flu outbreak provides rare study material 3Finding keys to glioblastoma therapeutic resistance 2
... why Starbucks puts boxes of breath mints close to the ... in your mouth, strong enough to startle your co-workers too. ... by renowned breath specialist Prof. Mel Rosenberg of TAU,s Sackler ... the bacteria that lead to bad breath. New laboratory tests ...
... in German . , Mitochondria are ... harbor an elaborately folded inner membrane. It holds a ... cavities (cristae). The narrow shape of the entrance or ... the intracristal space and storage of molecules. Cytochrome c, ...
... and Wilfrid Laurier University today announce the launch ... a visible point of open access archiving of ... community. Built on BioMed Central,s "Open ... access knowledge and technology experience, Laurier IR is ...
Cached Biology News:A breath mint made from... coffee? 2How mitochondria get their membranes bent 2'Canadian excellence' strengthened by extensive adoption of open access 2
Recombinant Rhesus Monkey IFN Alpha Activity: 2.9 x 10 8 u/mg...
... space and organize gloves, safety glasses, ... are the perfect benchtop storage bins ... processing and manufacturing. Clear static-dissipative PVC ... they attract. Many other sizes and ...
... Ultrapure C 25 H 27 N 2 ... PRODUCT SPECIFICATIONS Form: Dark burgundy metallic powder Identity: ... 2 O, 1 cm): greater than or equal ... Drying: less than or equal to 10.0% lambda ...
...
Biology Products: